A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OXFORD BIOMEDICA PLC ORD 50P operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 165M | 165M | 112M | 173M | 196M |
| Net Income | -55M | -55M | -197M | -56M | 26M |
| EPS | $-0.53 | $-0.53 | $-2.04 | $-0.51 | $0.31 |
| Free Cash Flow | -74M | -74M | -48M | -36M | 22M |
| ROIC | - | -131.0% | -104.3% | -13.4% | 17.7% |
| Gross Margin | 41.2% | 41.2% | 44.4% | 49.4% | 57.9% |
| Debt/Equity | 0.00 | 0.70 | 0.52 | 0.70 | 0.09 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -50M | -50M | -230M | -37M | 29M |
| Operating Margin | -30.6% | -30.6% | -205.7% | -21.6% | 14.5% |
| ROE | -75.7% | -66.8% | -102.5% | -20.3% | 10.1% |
| Shares Outstanding | 103M | 103M | 97M | 109M | 83M |
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 196M | 173M | 112M | 165M | 165M |
| Gross Margin | 57.9% | 49.4% | 44.4% | 41.2% | 41.2% |
| R&D | -55M | -75M | -14M | -5.8M | -5.8M |
| SG&A | 140M | N/A | N/A | 124M | 124M |
| EBIT | 29M | -37M | -230M | -50M | -50M |
| Op. Margin | 14.5% | -21.6% | -205.7% | -30.6% | -30.6% |
| Net Income | 26M | -56M | -197M | -55M | -55M |
| Net Margin | 13.3% | -32.3% | -175.9% | -33.5% | -33.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | 17.7% | -13.4% | -104.3% | -131.0% | N/A |
| ROE | 10.1% | -20.3% | -102.5% | -66.8% | -75.7% |
| ROA | N/A | N/A | N/A | N/A | 0.0% |
| Cash Flow | |||||
| Op. Cash Flow | 35M | -16M | -36M | -65M | -65M |
| Free Cash Flow | 22M | -36M | -48M | -74M | -74M |
| Owner Earnings | 35M | -16M | -36M | -65M | -65M |
| CapEx | 13M | 20M | 12M | 9.6M | 9.6M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | 9.6M |
| D&A | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 37.2% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 39M | 0 | 596K | 596K |
| Balance Sheet | |||||
| Net Debt | -127M | 28M | -81M | -26M | -78M |
| Cash & Equiv. | 150M | 174M | 129M | 78M | 78M |
| Long-Term Debt | N/A | N/A | 48M | 51M | 51M |
| Debt/Equity | 0.09 | 0.70 | 0.52 | 0.70 | 0.00 |
| Interest Coverage | 23.4 | -1.8 | -19.9 | -3.5 | -3.5 |
| Equity | 258M | 291M | 92M | 73M | 73M |
| Total Assets | N/A | N/A | N/A | N/A | 0 |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -228M | -245M | -440M | -511M | -511M |
| Working Capital | 179M | 192M | 121M | 96M | 96M |
| Current Assets | 225M | 266M | 176M | 170M | 170M |
| Current Liabilities | 46M | 74M | 55M | 75M | 75M |
| Per Share Data | |||||
| EPS | 0.31 | -0.51 | -2.04 | -0.53 | -0.53 |
| Owner EPS | 0.42 | -0.14 | -0.37 | -0.63 | -0.63 |
| Book Value | 3.08 | 2.66 | 0.96 | 0.71 | 0.71 |
| Cash Flow/Share | 0.42 | -0.14 | -0.37 | -0.63 | -0.53 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 83.5M | 109.4M | 96.6M | 103.4M | 103.4M |
| Valuation | |||||
| P/E Ratio | 47.2 | -9.6 | -1.4 | -9.9 | -11.7 |
| P/FCF | 54.7 | N/A | N/A | N/A | N/A |
| EV/EBIT | 37.7 | N/A | N/A | N/A | N/A |
| Price/Book | 4.7 | 1.8 | 2.9 | 7.5 | 8.9 |
| Price/Sales | 6.1 | 3.1 | 2.4 | 3.3 | 3.9 |
| FCF Yield | 1.8% | -6.7% | -17.7% | -13.6% | -11.5% |
| Market Cap | 1.2B | 533M | 271M | 547M | 647M |
| Avg. Price | 16.78 | 6.89 | 4.60 | 3.98 | 6.25 |
| Year-End Price | 14.42 | 4.87 | 2.80 | 5.29 | 6.25 |
OXFORD BIOMEDICA PLC ORD 50P passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 48.2%. At current prices, the estimated annualized return to fair value is -13.1%.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a 5-year average return on invested capital (ROIC) of -57.8%. This is below average and may indicate limited pricing power.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a market capitalization of $647M. It is classified as a small-cap stock.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) does not currently pay a regular dividend.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) operates in the Biotechnology industry, within the Healthcare sector.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) reported annual revenue of $165 million in its most recent fiscal year, based on SEC EDGAR filings.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a net profit margin of -33.5%. The company is currently unprofitable.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) generated $-74 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a debt-to-equity ratio of 0.70. This indicates moderate leverage.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) reported earnings per share (EPS) of $-0.53 in its most recent fiscal year.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a return on equity (ROE) of -66.8%. A negative ROE may indicate losses or negative equity.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a 5-year average gross margin of 48.2%. This indicates decent pricing power.
The Ledger Terminal provides 4 years of financial data for OXFORD BIOMEDICA PLC ORD 50P (OXB-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OXFORD BIOMEDICA PLC ORD 50P (OXB-L) has a book value per share of $0.71, based on its most recent annual SEC filing.
No recent press releases.